Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1073217 | 0.85 | ALDH1A1 (0.49) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL3447697 | 0.84 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL1284022 | 0.83 | ALDH1A1 (0.47) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| Hydrochloric Acid SCHEMBL9801852 | 0.80 | ALDH1A1 (0.45) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL23207822 | 0.80 | TSHR (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL27973107 | 0.79 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL5225500 | 0.79 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL24818335 | 0.79 | PKM (0.32) | ALDH1A1PIK3CD | |
| SCHEMBL460924 | 0.78 | ALDH1A1 (0.53) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| Iodide SCHEMBL11829332 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| EP-0409565-A1 | Rubber composition useful for tires | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | ALDH1A1 3413/4885CYP3A4 4863/4885CYP2C9 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.